Image_1_Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form − 5 Years Follow-Up.JPEG by Lyudmila Vladimirova-Kitova (11537353)

“…Initial treatment, based on European recommendations, included Atorvastatin 20 mg and Ezetimibe 10 mg and led to a decrease in LDL-C by 46% for 5 months; however, the patient developed severe statin intolerance. …”

Supplemental data 3. by Zachary J. Hough (20840430)

“…Akt3 null hearts at midgestation (E14.5), a stage in which proliferation is occurring, have decreased Aurora B expression, increased CRM-1 expression, decreased proliferation, and increased apoptosis. …”

Pharmacological induction of mitochondrial dysfunction results in micronuclei and nuclear blebbing. by Zachary J. Hough (20840430)

Open data. by Larissa Brazolotto Ferreira (17671168)

“…</p><p>Results</p><p>There was a significant decrease in BMD in the lumbar spine (1.107 ± 0.109 and 1.075 ± 0.112 g/cm²; <i><i>p</i></i> < 0.001), total body (1.135 ± 0.086 and 1.119 ± 0.085 g/cm²; <i><i>p</i></i> < 0.001), and total proximal femur over the six months of EBF compared to the values obtained from the same EBF group at 15 days postpartum (mean percentage decreases in BMD of −3.4 ± 3.7% (<i><i>p</i></i> < 0.001) in lumbar spine, −2.5 ± 3.4% (<i><i>p</i></i> < 0.001) in total proximal femur, and −1.7 ± 1.9% (<i><i>p</i></i> = 0.001) in total body). …”

Spatial variation within and across lakes in chl-a trends (1997–2020). by Benjamin M. Kraemer (7526225)

Fig 1 - by Million Phiri (14053278)

Changes of the normalized volume V/V₀ in glioblastoma cell lines in response to sucrose- and inositol-substituted solutions of different osmolalities (LHS and RHS column... by Simon Memmel (518138)

“…As expected, the initial swelling (2–3 min) of all cell lines increased in magnitude with decreasing osmolality of hypotonic media. But the secondary volume changes (time >5 min) were found to be strongly dependent on both the cell type and the extracellular osmolyte. …”

Future ozone-related acute excess mortality under climate and population change scenarios in China: A modeling study by Kai Chen (129938)

“…Using historical ozone monitoring data, we performed bias correction and spatially downscaled future ozone projections at a coarse spatial resolution (2.0° × 2.5°) for the period April 27, 2053, to October 31, 2055 (2053–2055), from a global chemistry–climate model to a fine spatial resolution (0.25° × 0.25°) under 2 Intergovernmental Panel on Climate Change Representative Concentration Pathways (RCPs): RCP4.5, a moderate global warming and emission scenario where global warming is between 1.5°C and 2.0°C, and RCP8.5, a high global warming and emission scenario where global warming exceeds 2.0°C. …”

Heterogeneity analysis. by Ying Zhao (16546)

“…Heterogeneity tests, horizontal pleiotropy tests, and the leave-one-out method were applied to evaluated the robustness of the MR analysis results. A total of 117 SNPs were employed as instrumental variables (<i>P</i> < 5 × 10⁻⁸). …”

Reverse MR analysis data. by Ying Zhao (16546)

“…Heterogeneity tests, horizontal pleiotropy tests, and the leave-one-out method were applied to evaluated the robustness of the MR analysis results. A total of 117 SNPs were employed as instrumental variables (<i>P</i> < 5 × 10⁻⁸). …”

SNP dressing by screening. by Ying Zhao (16546)

“…Heterogeneity tests, horizontal pleiotropy tests, and the leave-one-out method were applied to evaluated the robustness of the MR analysis results. A total of 117 SNPs were employed as instrumental variables (<i>P</i> < 5 × 10⁻⁸). …”

Confirmatory factor analysis for the six-factor model of the VIJS. by Thuy Thi Phuong Nguyen (14059656)

Image_6_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_1_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_7_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_4_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_8_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_9_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_2_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”

Image_3_A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins.TIF by Sarra El-Soussi (11228799)

“…The protein expression of tumorigenic NMYC, Sox-2, Oct-4, FABP5, and HMGA1 significantly decreased 48 h post-drug treatment, whereas cleaved PARP1/caspase-3 and γH2AX increased 72 h post-drug treatment, compared with vehicle-treated cells in the MYCN-amplified IMR-32 cell line. …”